Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Moderate Buy” by Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned an average rating of “Moderate Buy” from the nineteen ratings firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $187.39.

A number of equities research analysts recently weighed in on the company. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Bank of America increased their price target on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a research report on Friday, June 21st. Piper Sandler cut their price objective on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Leerink Partners increased their target price on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. Finally, Evercore ISI upgraded shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and lowered their target price for the company from $185.00 to $179.00 in a research note on Thursday, August 8th.

Sarepta Therapeutics Trading Up 0.1 %

NASDAQ:SRPT opened at $127.21 on Monday. The firm has a 50-day simple moving average of $137.26 and a 200-day simple moving average of $132.75. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $173.25. The firm has a market cap of $12.02 billion, a P/E ratio of 1,156.45 and a beta of 0.81. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The company had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. Sarepta Therapeutics’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.27) earnings per share. Equities analysts anticipate that Sarepta Therapeutics will post 1.47 EPS for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Michael Andrew Chambers purchased 37,038 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Principal Securities Inc. acquired a new position in shares of Sarepta Therapeutics during the 4th quarter worth about $26,000. Dimensional Fund Advisors LP grew its stake in Sarepta Therapeutics by 10.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 224,201 shares of the biotechnology company’s stock valued at $21,621,000 after acquiring an additional 20,923 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Sarepta Therapeutics by 125.3% in the 4th quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock valued at $4,777,000 after acquiring an additional 27,549 shares during the last quarter. Norges Bank purchased a new position in Sarepta Therapeutics in the 4th quarter worth approximately $80,697,000. Finally, UBS Group AG boosted its holdings in shares of Sarepta Therapeutics by 26.5% during the 4th quarter. UBS Group AG now owns 276,276 shares of the biotechnology company’s stock worth $26,641,000 after purchasing an additional 57,805 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.